EAACI

HAMPTON, N.J., June 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company’s barzolvolimab program will be presented at the…

-Rapid, profound and durable responses across multiple dosing groups with favorable safety profile--Mean reduction from baseline in urticaria activity (UAS7) of 66.6% in 1.5 mg/kg dose…

- 95% complete response rate after single dose of CDX-0159 -- Rapid, profound and durable responses offer patients opportunity for quick, lasting, meaningful relief -- Median duration of…

ZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral…

RESEARCH TRIANGLE PARK, N.C., July 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy…